Latham & Watkins Advises Zevra on Public Offering of Common Stock

Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (Zevra), has announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of US$6.50 per share, for total gross proceeds of approximately US$60 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP advised Zevra in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associates Angel Marcial and Yulong Li. Advice was also provided on FDA regulatory matters by Elizabeth Richards.